Cargando…
"Flagellated" cancer cells propel anti-tumor immunity
The use of innate immune receptor agonists in cancer therapies has suffered from many drawbacks. Our recent observations suggest that some of these hurdles can be overcome by introducing flagellin into tumor cells to promote tumor antigen presentation by dendritic cells (DCs) and simultaneously trig...
Autores principales: | Garaude, Johan, Blander, J. Magarian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489752/ https://www.ncbi.nlm.nih.gov/pubmed/23162764 http://dx.doi.org/10.4161/onci.20305 |
Ejemplares similares
-
Attacking tumor cells with a dual ligand for innate immune receptors
por: Garaude, Johan, et al.
Publicado: (2012) -
“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012) -
Distinct anti-tumoral functions of adaptive immune cells in liver cancer
por: Schneider, Carlo, et al.
Publicado: (2012) -
Host CD73 impairs anti-tumor immunity
por: Salmi, Marko, et al.
Publicado: (2012) -
A novel role for granzymes in anti-tumor immunity
por: Hoves, Sabine, et al.
Publicado: (2012)